et al. et al. et al. et al. et al.
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia

Silke Walleser A D , Glenn Salkeld B and Basil Donovan B C
+ Author Affliations
- Author Affliations

A NHMRC Clinical Trials Centre, University of Sydney, NSW 2050, Australia.

B STEP (Screening Test Evaluation Program) School of Public Health, University of Sydney, NSW 2006, Australia.

C National Centre in HIV Epidemiology & Clinical Research, University of New South Wales, Sydney, NSW 2001, Australia.

D Corresponding author. Email: swalleser@ctc.usyd.edu.au

Sexual Health 3(4) 225-234 https://doi.org/10.1071/SH06016
Submitted: 6 March 2006  Accepted: 13 October 2006   Published: 17 November 2006

Abstract

Background: In Australia, there is no published study on the cost effectiveness of screening for chlamydia. The aim of this study was to examine the cost effectiveness of a hypothetical screening programme for chlamydia based on annual opportunistic testing of all women 25 years of age or younger consulting a general practitioner, compared with no screening. Methods: A decision–analytic modelling approach was used to determine the incremental cost effectiveness ratio (ICER) of screening compared with no screening over 25 years. The analysis measured Australian health-care costs and benefits were assessed in terms of quality-adjusted life years (QALYs). Results: The analysis resulted in a cost per QALY of $2968 for screening. One-way sensitivity analyses on all variables, and multi-way sensitivity analyses on some variables, showed a wide range for the cost effectiveness, from dominance (where screening is effective and saves money overall) to an ICER of $67 715 per QALY. Conclusions: The results indicate that annual opportunistic screening for chlamydia in women under 25 is a potentially worthwhile undertaking. However, the analysis also highlights uncertainties around the natural history of chlamydia and the effectiveness of chlamydia screening. Given these uncertainties, the need for further primary data collection in these areas becomes apparent.


Acknowledgements

The authors acknowledge and appreciate the assistance of Ms Kirsten Howard in the use of the modelling software DATA that contributed to the design of the decision model.


References


[1] National Centre in HIV Epidemiology and Clinical Research. HIV/AID, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2005. Sydney: The University of NSW; 2005.

[2] Chen MY,  Donovan B. Genital Chlamydia trachomatis infection in Australia: epidemiology and clinical implications. Sex Health 2004; 1(3 Suppl): 189–96.
CrossRef | PubMed |

[3] Bowden FJ,  Tabrizi SN,  Garland SM,  Fairley CK. MJA practice essentials: sexually transmitted infections: new diagnostic approaches and treatments. Med J Aust 2002; 176 551–7.
PubMed |

[4] Nelson HD,  Helfand M. Screening for chlamydial infection. Am J Prev Med 2001; 20(3 Suppl): 95–107.
CrossRef | PubMed |

[5] Simms I,  Stephenson J. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know? Sex Transm Infect 2000; 76(2): 80–7.
CrossRef | PubMed |

[6] Heal C,  Jones B,  Veitch C,  Lamb S,  Hodgens S,  Browning S,  Butler H,  Carey M. Screening for chlamydia in general practice. Aust Fam Physician 2002; 31(8): 779–82.
PubMed |

[7] Chen MY,  Donovan B. Changes in testing methods for genital Chlamydia trachomatis in New South Wales, Australia, 1999–2002. Sex Health 2005; 2 251–3.
CrossRef | PubMed |

[8] Egger M,  Low N,  Smith GD,  Lindblom B,  Herrmann B. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. BMJ 1998; 316 1776–80.
PubMed |

[9] Hillis SD,  Nakashima A,  Amsterdam L,  Pfister J,  Vaughn M,  Addiss D, et al. The impact of a comprehensive chlamydia prevention program in Wisconsin. Fam Plann Perspect 1995; 27(3): 108–11.
CrossRef | PubMed |

[10] Herrmann BF,  Johansson AB,  Mardh P-A. A retrospective study of efforts to diagnose infections by Chlamydia trachomatis in a Swedish county. Sex Transm Dis 1991; 18(4): 233–7.
PubMed |

[11] Scholes D,  Stergachis A,  Heidrich FE,  Andrilla H,  Holmes KK,  Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334(21): 1362–6.
CrossRef | PubMed |

[12] The national strategy for sexual health and HIV. London: Department of Health; 2001.

[13] Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51 1–84.


[14] Chlamydia strategy for Victoria 2001–2004. Melbourne: Victorian Government Department of Human Services, Public Health Division; 2001.

[15] Clinical Guidelines for the Management of sexually transmissible infections among priority populations. Sydney: The Royal Australasian College of Physicians – Adult Medicine Division – Australasian Chapter of Sexual Health Medicine; 2004.

[16] Hollblad-Fadiman K,  Goldman SM. American College of Preventive Medicine practice policy statement: screening for Chlamydia trachomatis. Am J Prev Med 2003; 24(3): 287–92.
CrossRef | PubMed |

[17] Honey E,  Augood C,  Templeton A,  Russell I,  Paavonen J,  Mardh PA, et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect 2002; 78(6): 406–12.
CrossRef | PubMed |

[18] Golden MR,  Schillinger JA,  Markowitz LE,  St. Louis ME. Duration of untreated genital infections with Chlamydia trachomatis – a review of the literature. Sex Transm Dis 2000; 27(6): 329–37.
PubMed |

[19] Hu D,  Hook EW,  Goldie SJ. Screening for Chlamydia trachomatis in Women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med 2004; 141 501–13.
PubMed |

[20] Lau C-Y,  Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections – a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29(9): 497–502.
PubMed |

[21] Chen MY,  Ryder N,  Donovan B. Completeness and timeliness of treatment for chlamydia within a sexual health service. Int J STD AIDS 2004; 15 762–4.
CrossRef | PubMed |

[22] Beigi RH,  Wiesenfeld HC. Pelvic inflammatory disease: new diagnostic criteria and treatment. Obstet Gynecol Clin North Am 2003; 30 777–93.
CrossRef | PubMed |

[23] Molano M,  Meijer CJLM,  Weiderpass E,  Arslan A,  Posso H,  Franceschi S, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005; 191 907–16.
CrossRef | PubMed |

[24] Stratton KR , Durch JS , Lawrence RS . Vaccines for the 21st century: a tool for decisionmaking. Washington, DC: National Academy Press; 2000.

[25] Chen MY,  Pan Y,  Britt H,  Donovan B. Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices. Int J STD AIDS 2006; 17 384–6.
CrossRef | PubMed |

[26] van Valkengoed IG,  Postma MJ,  Morre SA,  van den Brule AJ,  Meijer CJ,  Bouter LM,  Boeke AJ. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect 2001; 77(4): 276–82.
CrossRef | PubMed |

[27] Genc M,  Mardh A. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann Intern Med 1996; 124(1): 1–7.
PubMed |

[28] Westrom L,  Joesoef R,  Reynolds G,  Hagdu A,  Thompon SE. Pelvic inflammatory disease and fertility – a cohort study of 1 844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19(4): 185–92.
PubMed |

[29] Australian Institute of Health and Welfare (AIHW). Australia’s Mothers and babies 2002. Canberra: AIHW; 2003.

[30] Australian Government – Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Canberra: Commonwealth of Australia; 2004.

[31] Australian Government – Department of Health and Ageing. Medicare Benefits Schedule Book. Canberra: Commonwealth of Australia; 2004.

[32] National Hospital Cost Data collection: Cost weights for AR-DRG version 4.2., round 7 (2002–03), public sector. Canberra: Department of Health; 2004. Available online at: www.health.gov.au/internet/wcms/publishing.nsf/Content/health-casemix-costing-fc_r7.htm [verified November 2006].

[33] Clinical profiles for public hospitals, AR-DRG v 5.0, Australia, 2000–01 Canberra: Commonwealth of Australia, Department of Health and Ageing; 2005.

[34] Ward B,  Rodger AJ,  Jackson TJ,  Ward B,  Rodger AJ,  Jackson TJ. Modelling the impact of opportunistic screening on the sequelae and public healthcare costs of infection with Chlamydia trachomatis in Australian women. Public Health 2006; 120(1): 42–9.
CrossRef | PubMed |

[35] George B , Harris A , Mitchell A . Cost-effectiveness analysis and the consistency of decision-making: evidence from pharmaceutical reimbursement in Australia 1991–1996. Working Paper 89. Melbourne: Centre for Health Program Evaluation, Monash University; 1999.

[36] Health Matters ABC . Infertility – costs and legal issues. ABC Online; 2005. Available online at: http://www.abc.net.au/health/features/infertility/costs.htm [verified October 2006].

[37] Ryan M. Valuing psychological factors in the provision of assisted reproductive techniques using the economic instrument of willingness to pay. J Econ Psychol 1998; 19 179–204.
CrossRef |

[38] Ratcliffe J . The economics of the IVF programme: a critical review. Working paper 20. Melbourne: Centre for Health Program Evaluation; 1992.

[39] Kohl KS,  Markowitz LE,  Koumans EH. Developments in the screening for Chlamydia trachomatis: a review. Obstet Gynecol Clin North Am 2003; 30(4): 637–58.
CrossRef | PubMed |

[40] Australian Institute of Health and Welfare (AIHW). Cervical screening in Australia 1999–2000. Cancer Series No. 16. Canberra: AIHW; 2002.

[41] van Valkengoed IG,  Morre SA,  van den Brule AJ,  Meijer CJ,  Bouter LM,  Boeke AJ. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes–implications for cost-effectiveness analyses.  Int J Epidemiol 2004; 33(2): 416–25.
CrossRef | PubMed |

[42] Wiesenfeld HC,  Hillier SL,  Krohn MA,  Amortegui A,  Heine RP,  Landers DV,  Sweet RL. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100(3): 456–63.
CrossRef | PubMed |

[43] Wolner-Hanssen P. Silent pelvic inflammatory disease: is it overstated? Obstet Gynecol 1995; 86(3): 321–5.
CrossRef | PubMed |

[44] Barratt A,  Irwig L,  Glasziou P,  Cumming RG,  Raffle A,  Hicks N,  Gray JA,  Guyatt GH. Users’ guide to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-based medicine working group. JAMA 1999; 281 2029–34.
CrossRef | PubMed |

[45] Honey E,  Templeton A. Prevention of pelvic inflammatory disease by the control of C. trachomatis infection. Int J Gynaecol Obstet 2002; 78 257–61.
CrossRef | PubMed |

[46] Welte R,  Postma M,  Leidl R,  Kretzschmar M,  Welte R,  Postma M, et al. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005; 32(8): 474–83.
CrossRef | PubMed |

[47] LaMontagne D,  Fenton KA,  Randall S,  Anderson S,  Carter P. Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. Sex Transm Infect 2004; 80 335–41.
CrossRef | PubMed |

[48] Watson EJ,  Templeton A,  Russell I,  Paavonen J,  Mardh PA,  Stary A,  Pederson BS. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002; 51 1021–31.
PubMed |

[49] Walker CK,  Kahn JG,  Washington AE,  Peterson HB,  Sweet RL. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168 969–78.
PubMed |

[50] Chen MY,  Fairley CK,  Donovan B. Discordance between trends in chlamydia notifications and hospital admission rates for chlamydia related diseases in New South Wales, Australia. Sex Transm Infect 2005; 81 318–22.
CrossRef | PubMed |

[51] Ness RB,  Soper DE,  Holley RL,  Peipert J,  Randall H,  Sweet RL, et al. Effectiveness of inpatiet and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186 929–37.
CrossRef | PubMed |

[52] Buchan H,  Vessey M,  Goldacre M,  Fairweather J. Morbidity following pelvic inflammatory disease. Br J Obstet Gynaecol 1993; 100 558–62.
PubMed |

[53] Safrin S,  Schachter J,  Dahrouge D,  Sweet RL. Long-term sequelae of acute pelvic inflammatory disease – a retrospective cohort study. Am J Obstet Gynecol 1992; 166(4): 1300–5.
PubMed |



Rent Article (via Deepdyve) Export Citation Cited By (13)